The clinically relevant MEK inhibitor mirdametinib combined with D-cycloserine and prediction error disrupts fear memory in PTSD models
2024

Mirdametinib Disrupts Fear Memory in PTSD Models

Sample size: 167 publication 10 minutes Evidence: high

Author Information

Author(s): Raut Sanket B., Joly Fanny, Haass Nikolas K., Eri Rajaraman, Canales Juan J., Benedek David M., Ursano Robert J., Johnson Luke R.

Primary Institution: University of Tasmania

Hypothesis

Can the MEK inhibitor mirdametinib, combined with D-cycloserine and prediction error, disrupt fear memory in PTSD models?

Conclusion

Mirdametinib can disrupt fear memory reconsolidation when combined with memory destabilization strategies, offering a potential treatment for PTSD.

Supporting Evidence

  • Mirdametinib disrupted weak fear memory and reduced ERK phosphorylation in the lateral amygdala.
  • Prediction error was effective in labilizing weak fear memory.
  • Combined D-cycloserine and prediction error effectively labilized strong fear memory.
  • Mirdametinib did not affect retrieval of spatial memory or locomotor activity.
  • The effect of mirdametinib was specific to reconsolidation and not observed without memory reactivation.

Takeaway

This study shows that a drug called mirdametinib can help change bad memories in mice, which might help people with PTSD feel better.

Methodology

The study used C57BL/6 mice and an auditory fear conditioning paradigm to test the effects of mirdametinib on fear memory reconsolidation.

Limitations

The study was conducted in mice, and the effects on human PTSD patients are yet to be determined.

Participant Demographics

Male C57BL/6 mice were used in the experiments.

Statistical Information

P-Value

p<0.001

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.1038/s41398-024-03190-6

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication